WellSky and uMed Partner to Boost Home-Based Clinical Trials Access in the U.S. – Wednesday, December 17, 2025

WellSky and uMed have announced a strategic partnership aimed at expanding access to home-based clinical trials across the United States. This collaboration seeks to enhance clinical trial accessibility by leveraging the combined strengths of both companies in healthcare technology and home-based care.

Who should care: hospital CIOs, clinical operations leaders, healthcare IT directors, compliance officers, and medical technology decision-makers.

What happened?

WellSky, a leader in healthcare technology solutions, and uMed, a platform specializing in patient recruitment for clinical trials, have joined forces to expand the reach of home-based clinical trials nationwide. This initiative is designed to make clinical trials more accessible by enabling patients to participate from their homes, thereby overcoming traditional barriers such as travel requirements and the time constraints associated with in-person visits. By integrating WellSky's extensive healthcare network with uMed's patient engagement capabilities, the partnership aims to streamline patient recruitment and participation in clinical research. This collaboration not only enhances convenience for patients but also seeks to increase the diversity of trial participants—a critical factor for ensuring that research findings are broadly applicable across different populations. The expansion is expected to offer a scalable solution for conducting decentralized trials, a model that has gained momentum in the industry due to its ability to reach a wider demographic and improve patient retention rates. By reducing logistical hurdles, this approach can help accelerate the pace of clinical research and improve overall trial efficiency. Together, WellSky and uMed are positioned to address longstanding challenges in clinical trial enrollment and engagement by combining technology-driven patient outreach with home-based care delivery. This partnership represents a significant step toward transforming how clinical trials are conducted, making them more patient-centric and adaptable to evolving healthcare needs.

Why now?

The timing of this partnership aligns with the growing adoption of decentralized clinical trials, which have surged in popularity over the past 18 months. This shift is driven by the need to improve patient access and engagement while accelerating medical research by overcoming logistical challenges inherent in traditional trial models. The COVID-19 pandemic underscored the importance of remote healthcare solutions, prompting a reevaluation of clinical trial methodologies. Consequently, collaborations like the one between WellSky and uMed are emerging to meet the increasing demand for flexible, patient-centric research approaches that can adapt to changing healthcare landscapes.

So what?

This partnership carries significant implications for the healthcare industry, particularly in enhancing operational efficiency and patient outcomes. By enabling home-based participation, WellSky and uMed reduce the logistical burden on patients, which can lead to faster recruitment and improved retention in clinical trials. This acceleration has the potential to speed up the development and delivery of new treatments to the market, benefiting patients and healthcare providers alike. For hospitals and biotech companies, this collaboration offers a practical model for integrating decentralized trials into existing research strategies. Embracing this approach can lead to more robust data collection, greater participant diversity, and ultimately higher trial success rates. As decentralized trials become more mainstream, organizations that adapt early will be better positioned to leverage these advancements for competitive advantage.

What this means for you:

• For hospital CIOs: Consider integrating decentralized trial capabilities into existing IT infrastructures to enhance patient outreach and streamline data collection.
• For clinical operations leaders: Evaluate the potential for increased patient enrollment and retention through home-based trial models to improve trial outcomes.
• For healthcare IT directors: Explore partnerships with technology platforms that facilitate remote patient monitoring and engagement to support decentralized research.

Quick Hits

• Impact / Risk: The partnership could significantly increase patient participation in clinical trials, improving the diversity and robustness of research data.
• Operational Implication: Hospitals and research institutions may need to adapt their infrastructures to effectively support decentralized trial models.
• Action This Week: Review current clinical trial processes for opportunities to integrate home-based options and brief executive teams on the benefits of decentralized trials.